RAD51 is a key protein in the homologous recombination (HR) pathway of DNA double-strand break repair, and HR represents a novel target for cancer therapy. Because imatinib (Gleevec) has been reported to reduce RAD51 protein levels, we tested the clonogenic survival for RT112, H1299, PANC1, and PC3 tumor cell lines of varying p53 status and normal GM05757 normal fibroblasts after exposure to single agent imatinib (0-20 micromol/L; 0-72 hours). We also combined imatinib with DNA damaging agent...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity.
If you are the owner of this record, you can report an update to it here: Report update to this record